Cristina Rebordosa, Reimar W Thomsen, Arlene K Tave, Morten Madsen, Daniel C Beachler, David Martinez, Raquel Garcia-Esteban, Estel Plana, Anita Tormos, Soulmaz Fazeli Farsani, Susana Perez-Gutthann, Manel Pladevall-Vila
AIM: To estimate risks of diabetic ketoacidosis (DKA), acute liver injury (ALI), acute kidney injury (AKI), chronic kidney disease (CKD), severe complications of urinary tract infection (UTI) and genital infection (GI) among patients with type 2 diabetes initiating empagliflozin versus those initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor. MATERIALS AND METHODS: In this large multinational, observational, new-user cohort study in UK, Danish and US healthcare data sources, patients initiated empagliflozin or a DPP-4 inhibitor between August 2014 and August 2019, were aged ≥18 years, and had ≥12 months' continuous health plan enrolment...
January 17, 2024: Diabetes, Obesity & Metabolism